Diabetic retinopathy therapeutic - Innovations In Sight

Drug Profile

Diabetic retinopathy therapeutic - Innovations In Sight

Alternative Names: Vitreosolve

Latest Information Update: 20 Apr 2015

Price : $50

At a glance

  • Originator VitreoRetinal Technologies
  • Developer Innovations In Sight
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetic retinopathy

Most Recent Events

  • 20 Apr 2015 No recent reports of development identified - Phase-III for Diabetic retinopathy in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top